TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16635636

Group type: EXPERIMENTAL
Intervention: Shock-absorbing pylons
Number of subjects: 17

Group type: COMPARATOR
Intervention: Rigid pylons
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: C-Leg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Mauch SNS knees
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Weekdays activity
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: General activity
Number of subjects: 17
Study: 14639800

Group type: EXPERIMENTAL
Intervention: DHA-enriched eggs (147 mg DHA/egg)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ordinary eggs (20 mg DHA/egg)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: DHA-enriched eggs (147 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Number of subjects: 153

Group type: COMPARATOR
Intervention: Ordinary eggs (20 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Number of subjects: 153
Study: 10868315

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.5 mg bid, titrated to a maximum of 6.0 mg tid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of L-dopa and ropinirole
Number of subjects: 24

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 24
Study: 8989068

Group type: EXPERIMENTAL
Intervention: Sparfloxacin (Spfx), 400 mg on day 1, then 200 mg once daily for 10 to 14 days
Number of subjects: 304

Group type: COMPARATOR
Intervention: Roxithromycin (ROXI), 150 mg twice daily for 10 to 14 days
Number of subjects: 304
Study: 1456812

Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 + 7)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (5 + 5)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 & 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aclarubicin in combination with cytarabine (7 + 3)
Number of subjects: 48
Study: 3904821

Group type: EXPERIMENTAL
Intervention: Spectacle correction of unusually hypermetropic refractions from age 1 year
Number of subjects: 0
Study: 31698825

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.1 mg/day
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.2 mg/day
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Pemafibrate 0.4 mg/day
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: Pemafibrate (all doses)
Number of subjects: 1253

Group type: COMPARATOR
Intervention: Pemafibrate and placebo
Number of subjects: 1253
Study: 29379953

Group type: EXPERIMENTAL
Intervention: Extended intervention (medication review, 3 motivational interviews, follow-up with primary care physician, pharmacy, and nursing home)
Number of subjects: 1467

Group type: EXPERIMENTAL
Intervention: Extended intervention
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Basic intervention (medication review)
Number of subjects: 1467
Study: 27301235

Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cleansed (Control)
Number of subjects: 73
Study: 24818608

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal-sleep control
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Stressor (Trier Social Stress Test)
Number of subjects: 26
Study: 22328287

Group type: EXPERIMENTAL
Intervention: HAIC plus systemic chemotherapy (combined therapy)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Systemic chemotherapy alone (monotherapy)
Number of subjects: 287
Study: 20123413

Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular conduction block anesthesia
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vazirani-Akinosi inferior alveolar nerve block
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Buccal-plus-lingual infiltrations
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (control)
Number of subjects: 97
Study: 17400836

Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shame
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guilt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of pervasive threat to the country's image
Number of subjects: 0
Study: 16082015

Group type: EXPERIMENTAL
Intervention: Women (female soccer players)
Number of subjects: 24
Study: 12216602

Group type: EXPERIMENTAL
Intervention: Preoperative electroacupuncture (EA) for 45 minutes before induction of general anaesthesia (GA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo EA for 45 minutes before induction of general anaesthesia (GA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative electroacupuncture (EA) for 45 minutes
Number of subjects: 90
Study: 10707439

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months) + Nicotine inhalers (6-12 units/day for up to 6 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nicotine inhalers (6-12 units/day for up to 6 months) + Placebo (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months)
Number of subjects: 100
Study: 8942551

Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Number of subjects: 103

Group type: COMPARATOR
Intervention: Open biopsy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Survey
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 103
Study: 1763608

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium followed by daily oral magnesium tablets
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo infusion followed by daily oral placebo tablets
Number of subjects: 58
Study: 7077524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Depressant
Number of subjects: 32
Study: 30096214

Group type: COMPARATOR
Intervention: Anti-CSG video
Number of subjects: 549

Group type: COMPARATOR
Intervention: Pro-CSG video
Number of subjects: 549

Group type: COMPARATOR
Intervention: Control group (neutral video)
Number of subjects: 549
Study: 29304744

Group type: EXPERIMENTAL
Intervention: High carotenoid diet (375 g/d high carotenoid vegetables, 300 g/d high carotenoid fruit, 40-60 ml extra-virgin olive oil)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Lower carotenoid diet (375 g/d lower carotenoid vegetables, 300 g/d lower carotenoid fruit, 40-60 ml PUFA based oil)
Number of subjects: 73
Study: 27135207

Group type: EXPERIMENTAL
Intervention: Adjunctive couples intervention (n=19)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pain programme only (n=26)
Number of subjects: 45
Study: 24211192

Group type: EXPERIMENTAL
Intervention: Telephone follow-up intervention (pre-discharge education and three follow-up calls)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 124
Study: 22314015

Group type: EXPERIMENTAL
Intervention: Print-based intervention tailored to participant's level of risk of CRC based on self-reported family history assessment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal ethical care (Control group).
Number of subjects: 0
Study: 19392814

Group type: EXPERIMENTAL
Intervention: Folic acid and sodium valproate
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 88
Study: 17986161

Group type: EXPERIMENTAL
Intervention: Tramadol added to transdermal fentanyl (group T)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Transdermal fentanyl alone (group F)
Number of subjects: 70
Study: 15379176

Group type: EXPERIMENTAL
Intervention: OPTIONS group (educational intervention for osteoporosis prevention)
Number of subjects: 693

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 693
Study: 11250849

Group type: EXPERIMENTAL
Intervention: Insecure re-employment
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Permanent exit from paid employment
Number of subjects: 666

Group type: COMPARATOR
Intervention: Secure re-employment
Number of subjects: 666
Study: 9665954

Group type: EXPERIMENTAL
Intervention: Collection of cervical secretions prior to Pap smear using Weck‐cel sponges
Number of subjects: 266

Group type: COMPARATOR
Intervention: Only Pap smear collection (control group)
Number of subjects: 266
Study: 8006492

Group type: EXPERIMENTAL
Intervention: Primary nursing and discharge teaching (n = 36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (primary and control)
Number of subjects: 72
Study: 2912719

Group type: EXPERIMENTAL
Intervention: Brand-name carbamazepine (Tegretol)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Generic carbamazepine (Parke-Davis)
Number of subjects: 10
Study: 814396

Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 40
Study: 31067189

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure target <130 mm Hg
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Standard blood pressure target <140 mm Hg
Number of subjects: 4983

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure target <130 mm Hg (after excluding patients with higher GFR and intensive glycemic control)
Number of subjects: 4983

Group type: COMPARATOR
Intervention: Standard blood pressure target <140 mm Hg (after excluding patients with higher GFR and intensive glycemic control)
Number of subjects: 4983
Study: 28145064

Group type: EXPERIMENTAL
Intervention: Pair-based refund (P-PBR)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Individual weight loss with individual refund (I-IR)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Partner with individual refund (P-IR)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No MCC (comparison)
Number of subjects: 77
Study: 24878686

Group type: EXPERIMENTAL
Intervention: Culturally adapted smoking cessation intervention (8 weekly 40-min counseling sessions with Korean-specific cultural elements)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard smoking cessation intervention (8 weekly 10-min counseling sessions not culturally adapted)
Number of subjects: 109
Study: 23134470

Group type: EXPERIMENTAL
Intervention: Daily everolimus (7.5 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Weekly everolimus (70 mg)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Daily everolimus (7.5 mg) in HBsAg‐seropositive patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Weekly everolimus (70 mg) in HBsAg‐seropositive patients
Number of subjects: 39
Study: 21606230

Group type: EXPERIMENTAL
Intervention: Powered bone marrow aspiration and biopsy device
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual technique
Number of subjects: 50
Study: 18206247

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids), 1.9g/day for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 16802891

Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Conscientiousness
Number of subjects: 200

Group type: COMPARATOR
Intervention: Task-induced stress conditions
Number of subjects: 200
Study: 15199081

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER 20 mg q12h for 1 day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Number of subjects: 126
Study: 12815774

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (7.5% - 1 ml/kg b.w.)
Number of subjects: 16
Study: 9297272

Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration (CHF)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Early amputation and restoration of diuresis combined with CHF
Number of subjects: 21
Study: 7686013

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 34
Study: 2952435

Group type: EXPERIMENTAL
Intervention: Random blood glucose measurement (thresholds: 6.1 mmol/l within 2 h of eating, 5.6 mmol/l at greater than 2 h of food)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Formal oral glucose tolerance test
Number of subjects: 110
Study: 29630800

Group type: EXPERIMENTAL
Intervention: 0.454% w/w stannous fluoride dentifrice
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP) dentifrice
Number of subjects: 104
Study: 28767209

Group type: EXPERIMENTAL
Intervention: Suvorexant (15 mg/d)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26184339

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral methods of exercise support
Number of subjects: 108

Group type: COMPARATOR
Intervention: Manual-based self-help for nutrition and exercise plus brief phone follow-ups
Number of subjects: 108
Study: 23515985

Group type: EXPERIMENTAL
Intervention: Hybrid total hip arthroplasty group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium (CoCr) total hip arthroplasty group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titanium total hip arthroplasty group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 21725509

Group type: EXPERIMENTAL
Intervention: Endosonography (EUS) for locoregional staging
Number of subjects: 62
Study: 19105461

Group type: EXPERIMENTAL
Intervention: Improved splint
Number of subjects: 92

Group type: COMPARATOR
Intervention: Traditional splint
Number of subjects: 92
Study: 17000363

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Echocardiographic assessment of left atrial function
Number of subjects: 42
Study: 15526194

Group type: EXPERIMENTAL
Intervention: Strawberry odor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soy sauce odor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined strawberry odor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imagined soy sauce odor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Odorless water
Number of subjects: 0
Study: 11748094

Group type: EXPERIMENTAL
Intervention: Left ventricle (LV) stimulation at the lateral free wall
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biventricular (BV) stimulation at the lateral free wall
Number of subjects: 30

Group type: COMPARATOR
Intervention: Left ventricle (LV) stimulation at the anterior wall
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biventricular (BV) stimulation at the anterior wall
Number of subjects: 30
Study: 9268234

Group type: EXPERIMENTAL
Intervention: Simvastatin 5 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day
Number of subjects: 36
Study: 8337639

Group type: EXPERIMENTAL
Intervention: Local anaesthesia with intravenous sedation
Number of subjects: 125

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 125
Study: 3526572

Group type: EXPERIMENTAL
Intervention: Conservative management (expectant management)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Oxytocin induction
Number of subjects: 317
Study: 29954367

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Modification (ILSM) program
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: ILSM program
Number of subjects: 256
Study: 26490353

Group type: COMPARATOR
Intervention: Fostamatinib 50-200 mg (single and multiple dosing)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fostamatinib 150 mg (single dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 and 200 mg (open-label study)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fostamatinib (all doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dried blood spot (DBS) sampling
Number of subjects: 80
Study: 24384459

Group type: EXPERIMENTAL
Intervention: Brief educational intervention (5-10 min group HPV educational intervention)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Brief educational intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (survey completion prior to education)
Number of subjects: 131
Study: 22795435

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublobar resection (with or without brachytherapy)
Number of subjects: 0
Study: 18832427

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10-20 mg/day (fixed 10 mg/day in Study 2) with venlafaxine 75 mg/day
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Aripiprazole 10-20 mg/day with escitalopram 10 mg/day
Number of subjects: 498

Group type: COMPARATOR
Intervention: Aripiprazole 2-20 mg/day (adjunctive therapy)
Number of subjects: 498
Study: 18695468

Group type: COMPARATOR
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Polyglactin mesh (MESH)
Number of subjects: 51
Study: 11446908

Group type: EXPERIMENTAL
Intervention: Amoxicillin-sulbactam 875/125 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 875/125 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulbactam 125 mg
Number of subjects: 12
Study: 9506730

Group type: EXPERIMENTAL
Intervention: G+T (three large gin with regular tonics, 0.5 g/kg alcohol and 60 g carbohydrate)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: G alone (same amount of alcohol with Slim‐line tonic, 0.5 g carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: T alone (regular tonic without alcohol)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: G+T
Number of subjects: 8
Study: 7890893

Group type: EXPERIMENTAL
Intervention: alpha‐2a interferon, 1 megaunit thrice weekly for 6 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no maintenance treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 53
Study: 3126012

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 10 mg/24 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31292822

Group type: EXPERIMENTAL
Intervention: Type D personality
Number of subjects: 1116

Group type: COMPARATOR
Intervention: No Type D personality
Number of subjects: 1116
Study: 27337519

Group type: EXPERIMENTAL
Intervention: Tribulus terrestris (750 mg in three divided doses for three months)
Number of subjects: 30
Study: 25977745

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg three times a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone (mPSL) 1 mg/kg three times a day
Number of subjects: 40
Study: 23681085

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/day)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 21972156

Group type: EXPERIMENTAL
Intervention: 0.2 mg of nitroglycerin plus 2.5 mg of verapamil (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 mg of verapamil alone (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison between Group 1 and Group 2
Number of subjects: 30
Study: 18775652

Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment under basal conditions in responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment after stimulation with phytohemagglutinin in responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol treatment in responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol and dexamethasone treatment in responders
Number of subjects: 0
Study: 17067450

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 711

Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 711
Study: 12712826

Group type: EXPERIMENTAL
Intervention: Cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Azithromycin 1 x 0.5 g (group II = 20 persons)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 40
Study: 10613936

Group type: EXPERIMENTAL
Intervention: Perfusion imaging-guided strategy (SPECT imaging results unblinded to the physician)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional strategy (results of the imaging test blinded to the physician)
Number of subjects: 46
Study: 9103292

Group type: EXPERIMENTAL
Intervention: 25,000 IU retinol daily for 5 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-10 mg isotretinoin daily for 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8397560

Group type: EXPERIMENTAL
Intervention: Fiber-enriched diet (40 to 80 gm of fiber per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-fiber dose (40 to 60 gm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fiber dose (70 to 80 gm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: American Diabetes Association recommended diet (20 gm or less of fiber)
Number of subjects: 0
Study: 30382392

Group type: EXPERIMENTAL
Intervention: Sensorimotor training (SMT), N = 10
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBV), N = 10
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oncological control group, N = 10
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy control group, N = 10
Number of subjects: 40
Study: 29582637

Group type: EXPERIMENTAL
Intervention: Swallowing exercises (University of Texas, MD Anderson Cancer Center Swallowing Exercise Protocol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no swallowing exercises)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing thin liquids
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing thick liquids
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing soft food
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing hard food
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing dry food
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Swallowing saliva
Number of subjects: 60